• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together almost 80 member organizations across the globe, united by a single purpose: driving global collaboration toward a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

Our Vision: A world free of ALS/MND

Our Aspiration: To drive global collaboration

Our Reach: We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose: Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

  • Bring focus to quality of life for PALS and their community: We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.
  • Include under-represented communities: By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.
  • Increase awareness of ALS/MND: By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.
  • Facilitate research coordination: By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.
  • Leverage collective capacity: By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.
  • Grow the community: By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Alliance Strategy 2026-2028: Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Annual Report 2024-2025: A review of the Alliance’s work and impact over the past year.

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Liam Dwyer, England

    Liam Dwyer, England

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Daniela Maria Daverio, Argentina

    Daniela Maria Daverio, Argentina

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Olga, Argentina

    Olga, Argentina

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Mark Miller, UK

    Mark Miller, UK

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Jon Newsome, USA

    Jon Newsome, USA

  • Steve

    Steve

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Art Eggert, USA

    Art Eggert, USA

  • Jean Waters, UK

    Jean Waters, UK

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Jason Goodman, USA

    Jason Goodman, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login